Naloxone shortage
Executive Summary
FDA contracts Canadian company Sabex to supply morphine antagonist pending shortage resolution. Narcan manufacturer Endo had experienced manufacturing difficulties due to DuPont plant shutdown (1"The Pink Sheet" March 26, In Brief). According to the American Society of Health-System Pharmacists, Endo plans to release back orders by early June, while Abbott expects releases in April and May. Sabex' naloxone will not be available for intrathecal use
You may also be interested in...
FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest
The Health Industry Group Purchasing Association is proposing that FDA offer a "safe haven" for manufacturers to discuss potential product discontinuations or supply disruptions
FDA Drug Shortage Role Should Focus On Prevention, GPOs Suggest
The Health Industry Group Purchasing Association is proposing that FDA offer a "safe haven" for manufacturers to discuss potential product discontinuations or supply disruptions
Endo Narcan
Shortages of naloxone are due to shutdown of DuPont sterile manufacturing facility, Endo explains (1"The Pink Sheet" March 19, p. 16). DuPont says manufacturing facility was closed for routine repair and maintenance. Endo expects production to be resumed by the end of March. DuPont's Manati, Puerto Rico facility received a warning letter in June 2000 for deviations from good manufacturing practices